Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia and its ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Societe Generale has recently reduced Merck & Co Inc (MRK) stock to Sell rating, as announced on March 11, 2024, according to Finviz. Earlier, on January 4, 2024, TD Cowen had raised the stock from a ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia, for the ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Mark Cuban, Reid Hoffman and other big names in business joined with Vice President Harris’s campaign for the launch of ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

Vice President Kamala Harris allies in the business community are trying to give her a boost over Donald Trump.

A group of business leaders are launching a new podcast in a bid to convince economy-minded swing voters to back Kamala ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...